FDA Approves DEPAKOTE ER — AbbVie Inc.

AbbVie Inc. solidified its foothold in the anticonvulsant market with the FDA approval of DEPAKOTE ER, the once-daily extended-release version of divalproex sodium, which is positioned to drive revenue growth by capitalizing on improved patient adherence compared to older formulations.